OncoMatch/Clinical Trials/NCT03696680
Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal
Is NCT03696680 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for hemorrhagic brain metastases.
This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cerebral stereotactic irradiation
Patient with prior cerebral stereotactic irradiation
Cannot have received: total brain irradiation
History of total brain irradiation
Lab requirements
Blood counts
Thrombocytopenia less than 100,000 cells / mm3 [excluded]
Thrombocytopenia less than 100,000 cells / mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify